189 related articles for article (PubMed ID: 18264124)
1. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.
Chou TC; Lin YF; Wu WC; Chu KM
Br J Pharmacol; 2008 Mar; 153(6):1281-7. PubMed ID: 18264124
[TBL] [Abstract][Full Text] [Related]
2. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
3. Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation.
Lee YM; Chen WF; Chou DS; Jayakumar T; Hou SY; Lee JJ; Hsiao G; Sheu JR
J Biomed Sci; 2010 Jun; 17(1):45. PubMed ID: 20525309
[TBL] [Abstract][Full Text] [Related]
4. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process.
Chou TC; Li CY; Yen MH; Ding YA
Biochem Pharmacol; 1999 Nov; 58(10):1657-63. PubMed ID: 10535758
[TBL] [Abstract][Full Text] [Related]
6. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets.
Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Trovati M
Eur J Clin Invest; 2001 May; 31(5):452-61. PubMed ID: 11380598
[TBL] [Abstract][Full Text] [Related]
7. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
Hagiwara M; Endo T; Kanayama T; Hidaka H
J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
[TBL] [Abstract][Full Text] [Related]
8. Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.
Ferreira MA; do Nascimento NR; de Sousa CM; Pessoa OD; de Lemos TL; Ventura JS; Schattner M; Chudzinski-Tavassi AM
Br J Pharmacol; 2008 Jul; 154(6):1216-24. PubMed ID: 18516074
[TBL] [Abstract][Full Text] [Related]
9. Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes.
Geng Y; Zhou L; Thompson WJ; Lotz M
J Biol Chem; 1998 Oct; 273(42):27484-91. PubMed ID: 9765278
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
Gordge MP; Hothersall JS; Noronha-Dutra AA
Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of cyclic GMP content by cyclic GMP-phosphodiesterase and guanylate cyclase in SHR with CsA-induced nephrotoxicity.
Hosogai N; Seki J; Goto T
Br J Pharmacol; 2001 Nov; 134(5):995-1002. PubMed ID: 11682447
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease.
Riddell DR; Graham A; Owen JS
J Biol Chem; 1997 Jan; 272(1):89-95. PubMed ID: 8995232
[TBL] [Abstract][Full Text] [Related]
13. LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation.
Mülsch A; Lückhoff A; Pohl U; Busse R; Bassenge E
Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):119-25. PubMed ID: 2552329
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide-independent down-regulation of soluble guanylyl cyclase by bacterial endotoxin in astroglial cells.
Baltrons MA; García A
J Neurochem; 1999 Nov; 73(5):2149-57. PubMed ID: 10537075
[TBL] [Abstract][Full Text] [Related]
15. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.
Roger S; Badier-Commander C; Paysant J; Cordi A; Verbeuren TJ; Félétou M
Br J Pharmacol; 2010 Nov; 161(5):1044-58. PubMed ID: 20977455
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
17. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors.
Salvemini D; Radziszewski W; Korbut R; Vane J
Br J Pharmacol; 1990 Dec; 101(4):991-5. PubMed ID: 1707709
[TBL] [Abstract][Full Text] [Related]
18. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.
Radomski MW; Palmer RM; Moncada S
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5193-7. PubMed ID: 1695013
[TBL] [Abstract][Full Text] [Related]
19. Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta.
Hussain MB; Hobbs AJ; MacAllister RJ
Br J Pharmacol; 1999 Nov; 128(5):1082-8. PubMed ID: 10556946
[TBL] [Abstract][Full Text] [Related]
20. The antiplatelet activity of Escherichia coli lipopolysaccharide is mediated through a nitric oxide/cyclic GMP pathway.
Sheu JR; Hung WC; Su CH; Lin CH; Lee LW; Lee YM; Yen MH
Eur J Haematol; 1999 May; 62(5):317-26. PubMed ID: 10359060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
